TELA Bio, Inc.
No SEC Form 4 filings for $TELA in the last 30 days.
See all $TELA insider activity →TELA Bio, Inc. (TELA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622768d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 TELA Bio Reports Second Quarter 2026 Financial Results MALVERN, PA, August 10, 2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction
TELA Bio, Inc. (TELA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001561921 0001561921 2026-08-03 2026-08-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor
TELA Bio, Inc. (TELA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001561921 0001561921 2026-06-09 2026-06-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor
Over the past 7 days, alphai's AI scored 2 news stories mentioning TELA (TELA Bio, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.
Recent TELA coverage spans financial news, corporate actions and earnings.
Guidance withdrawal and CEO-led strategy reset increase near-term uncertainty around revenue trajectory and cash runway, making TELA a higher-volatility trading candidate.
Leadership change can shift near-term strategy, execution priorities, and investor sentiment, especially if separation terms or guidance are later disclosed.
Share authorization increase can be modestly dilutive and may affect equity overhang expectations, but it is not a new operating milestone.
TELA Bio reported a modest revenue increase of 3% YoY in Q1 2026, driven by international sales and new product launches. The company is optimistic about the second half of 2026, supported by sales force expansion and board updates.
TELA Bio's upcoming participation in Piper Sandler's Healthcare Conference indicates ongoing investor engagement and potential positive developments. The bullish sentiment (score: 0.68747, label: 'Bullish') suggests market optimism. However, the actual impact on stock price remains uncertain and depends on subsequent disclosures and investor reactions.
alphai scores every news story that mentions TELA with an AI model for sentiment and relevance, and aggregates insider trades from TELA Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
TELA Bio, Inc. (TELA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622768d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 TELA Bio Reports Second Quarter 2026 Financial Results MALVERN, PA, August 10, 2026 -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction
4 min readTELA Bio, Inc. (TELA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001561921 0001561921 2026-08-03 2026-08-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor
3 min readTELA Bio, Inc. (TELA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001561921 0001561921 2026-06-09 2026-06-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor
2 min readTELA Bio reported Q1 2026 revenue of $19.1 million, a 3% year-over-year increase, driven by strong international sales and the launch of the Ovatex Long Term Resorbable Reinforcement Portfolio. The company expanded its sales force and updated its board to support future growth, reiterating a full-year revenue growth guidance of at least 8% over 2025. Management expressed confidence in a strong second half of 2026 due to these strategic initiatives.
3 min readMALVERN, Pa., Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- TELA Bio, Inc. ( NASDAQ:TELA ) , a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler's 37th Annual Healthcare ...
3 min readMALVERN, Pa., Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- TELA Bio, Inc. ( NASDAQ: TELA ) , a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler's 37th Annual Healthcare ...
2 min readMALVERN, Pa., Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- TELA Bio, Inc. ( "TELA Bio" ) ( NASDAQ: TELA ) , a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA ...
2 min readTELA Bio Inc ( NASDAQ:TELA ) reported mixed results for the third quarter on Thursday. The company posted quarterly losses of 19 cents per share which beat the analyst consensus estimate of losses of 20 cents per share.
3 min readTELA Bio (TELA) delivered earnings and revenue surprises of -11.76% and -5.53%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min readMALVERN, Pa., Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- TELA Bio, Inc. ( "TELA" ) , a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the pricing of an underwritten registered direct offering of 4,189,000 shares of its ...
2 min read
